Systemic mastocytosis emerging after azacitidine treatment of refractory anaemia with excess blasts type 2

Br J Haematol. 2014 Oct;167(2):147. doi: 10.1111/bjh.13024. Epub 2014 Jul 9.

Authors

Zhaodong Xu¹, Luke Shier, Mitchell Sabloff, Arleigh McCurdy, Dawn Sheppard, Christopher Bredeson

Affiliation

¹ Division of Haematopathology and Transfusion Medicine, Department of Pathology and Laboratory Medicine, The Ottawa Hospital, Ottawa, ON, Canada. zxu@toh.on.ca.

PMID: 25040664
DOI: 10.1111/bjh.13024

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Anemia, Refractory, with Excess of Blasts / drug therapy*
Anemia, Refractory, with Excess of Blasts / pathology
Antimetabolites, Antineoplastic / adverse effects*
Antimetabolites, Antineoplastic / therapeutic use
Azacitidine / adverse effects*
Azacitidine / therapeutic use
Fatal Outcome
Humans
Male
Mastocytosis, Systemic / chemically induced*
Mastocytosis, Systemic / pathology

Substances

Antimetabolites, Antineoplastic
Azacitidine